Home | Industry Information | Business News | Browse by Publication | B | BIOTECH Patent News

King and Palatin form strategic alliance to jointly develop and commercialize PT-141 as an innovative treatment for sexual dysfunction.

Publication: BIOTECH Patent News
Publication Date: 01-AUG-04
Format: Online - approximately 1262 words
Delivery: Immediate Online Access

Article Excerpt
King Pharmaceuticals, Inc. (Bristol, TN) and Palatin Technologies, Inc. (Cranbury, NJ) announced that they have entered into a strategic alliance to jointly develop and, on obtaining necessary regulatory approvals, commercialize Palatin's PT-141 for the treatment of male and female sexual is...

View more below

Read this article now - Try Goliath Business News - FREE!   
You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News - Free for 7 Days!
Tell Me More   Terms and Conditions

Purchase this article for $4.95

Already a subscriber? Log in to view full article

...dysfunction.

PT-141 the first compound in a new drug class called melanocortin receptor agonists under development to treat sexual dysfunction. This new chemical entity is being evaluated in phase II clinical trials studying the efficacy and safety profile of varying doses of this novel compound in men experiencing erectile dysfunction ("ED") and women experiencing female sexual dysfunction ("FSD"). The mechanism of action of PT-141 may offer important benefits over currently available products for the treatment of ED because it acts on the pathway that controls sexual function without acting directly on the vascular system. Clinical data indicates that PT-141 may be effective in treating a broad range of patients suffering from ED. The nasal formulation of PT-141 currently under development is as convenient as oral treatments, is more patient-friendly than invasive treatments for ED, such as injections and trans-urethral pellets, and appears to result in a rapid...

NOTE: All illustrations and photos have been removed from this article.



More articles from BIOTECH Patent News
University of Toronto obtains United States patent.(Brief Article), August 01, 2004
Oregon Health & Science University obtains United States patent.(Brief..., August 01, 2004
Applera obtains United States patent.(Brief Article), August 01, 2004
Prometheus gains settlement regarding autoimmune patents., August 01, 2004
ASCEND Therapeutics files patent applications for drug planned to trea..., August 01, 2004

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.